Replies to post #163005 on Elite Pharmaceuticals Inc (ELTP)

[dr_lowenstein]

I agree that elite MAY gain market share in the acute pain market IF their tech is any good at all, however, I do not see the ultimate leap into the chronic pain market. For once, there is the convenience issue, if you could take a once or twice a day product vs three times a day, the preference in every market research study is for the more convenient dosage form, But, the larger issue is that off label use in the opioid market is rapidly changing. The FDA is unlikely to approve promotion without chronic use clinical data (a two year program), the DEA tracks how these drugs are being prescribed and seeing scripts for long term use of products approved for acute pain only is s big red flag, and more importantly, the payors are very unlikely to pay for off label use in this field.

So, elite, MAY have a nice little product here, but that is about it .

[NASDAQ2020]

Elite has the extended release market oxy covered with ELI-201.

[no2koolaid]

Excellent, thank you. It is remarkable, is it not, that we seem to have forgotten such notable data? It makes one wonder how anyone would miss this compelling information. What is evident in the numbers, at least if we consider one of the factors for growth in the market, it is that we are seeing increasing medical and dental surgeries and with it the obvious need to address post surgical pain. Just another reason Elite is positioned well for success. Would you not agree?